Who We Are
About Amplia
Amplia is developing a type of drug called a FAK inhibitor which we hope will make cancers more vulnerable and responsive to currently used treatments.
Our FAK inhibitor, narmafotinib, aims to break down the fibrotic tissue shield that forms around pancreatic cancer cells to allow the chemotherapy to be more effective.
Amplia has successfully undertaken vital research and development milestones to get to this stage. Our clinical trial sites in the US are preparing to recruit and in Australia are active and we are recruiting participants for our Amplicity trial as we test if narmafotinib, used in combination with a standard of care chemotherapy drug regimen called FOLFIRINOX, is effective in treating metastatic pancreatic cancer.
